Prostaglandin D2 as a mediator of allergic asthma

Science

Volumn 287, Issue 5460, 2000, Pages 2013-2017

  Matsuoka, Toshiyuki ^a   Hirata, Masakazu ^a   Tanaka, Hiroyuki ^b   Takahashi, Yoshimasa ^b   Murata, Takahiko ^a   Kabashima, Kenji ^a   Sugimoto, Yukihiko ^c   Kobayashi, Takuya ^a   Ushikubi, Fumitaka ^a   Aze, Yoshiya ^d   Eguchi, Naomi ^e   Urade, Yoshihiro ^e   Yoshida, Nobuaki ^f   Kimura, Kazushi ^a   Mizoguchi, Akira ^a   Honda, Yoshihito ^a   Nagai, Hiroichi ^b   Narumiya, Shuh ^a  

^a KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d ONO PHARMACEUTICAL CO   (Japan)

^e OSAKA BIOSCIENCE INSTITUTE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN E; OVALBUMIN; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; ALLERGEN; GAMMA INTERFERON; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR;

AIRWAY; ALLERGIC ASTHMA; ANIMAL MODEL; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; EOSINOPHIL; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; ANIMAL; BLOOD; C57BL MOUSE; CROSS BREEDING; CYTOLOGY; FEMALE; GENE TARGETING; GENETICS; HUMAN; IMMUNOLOGY; LUNG; LUNG LAVAGE; LYMPHOCYTE; MALE; MAST CELL; METABOLISM; MUCUS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA; SECRETION;

ALLERGENS; ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; CROSSES, GENETIC; FEMALE; GENE TARGETING; HUMANS; IMMUNOGLOBULIN E; INTERFERON TYPE II; INTERLEUKINS; LUNG; LYMPHOCYTES; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; MUCUS; OVALBUMIN; PROSTAGLANDIN D2; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RESPIRATORY MUCOSA;

EID: 0034677595     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.287.5460.2013     Document Type: Article

References (39)

1. J. Bousquet et al., N. Engl. J. Med. 323, 1033(1990); D. S. Robinson et al., N. Engl. J. Med. 326, 298 (1992).
2. J. Bousquet et al., N. Engl. J. Med. 323, 1033(1990); D. S. Robinson et al., N. Engl. J. Med. 326, 298 (1992).
3. P. S. Foster, S. P. Hogan, A. J. Ramsay, K. I. Matthaei, I. G. Young, J. Exp. Med. 183, 195 (1996); D. B. Corry et al., Mol. Med. 4, 344 (1998); M. Wills-Karp et al., Science 282, 2258 (1998); G. Grünig et al., Science 282, 2261.
4. P. S. Foster, S. P. Hogan, A. J. Ramsay, K. I. Matthaei, I. G. Young, J. Exp. Med. 183, 195 (1996); D. B. Corry et al., Mol. Med. 4, 344 (1998); M. Wills-Karp et al., Science 282, 2258 (1998); G. Grünig et al., Science 282, 2261.
5. P. S. Foster, S. P. Hogan, A. J. Ramsay, K. I. Matthaei, I. G. Young, J. Exp. Med. 183, 195 (1996); D. B. Corry et al., Mol. Med. 4, 344 (1998); M. Wills-Karp et al., Science 282, 2258 (1998); G. Grünig et al., Science 282, 2261.
6. P. S. Foster, S. P. Hogan, A. J. Ramsay, K. I. Matthaei, I. G. Young, J. Exp. Med. 183, 195 (1996); D. B. Corry et al., Mol. Med. 4, 344 (1998); M. Wills-Karp et al., Science 282, 2258 (1998); G. Grünig et al., Science 282, 2261.
7. S. T. Holgate, Clin. Exp. Allergy 28 (suppl. 5), 97 (1998).
8. R. A. Lewis and K. F. Austen, Nature 293, 103 (1981); L. J. Roberts II, B. J. Sweetman, R. A. Lewis, K. F. Austen, J. A. Oates. N. Engl. J. Med. 303, 1400 (1980).
9. R. A. Lewis and K. F. Austen, Nature 293, 103 (1981); L. J. Roberts II, B. J. Sweetman, R. A. Lewis, K. F. Austen, J. A. Oates. N. Engl. J. Med. 303, 1400 (1980).
10. J. J. Murray et al., N. Engl. J. Med. 315, 800 (1986); M. C. Liu et al., Am. Rev. Respir. Dis. 142, 126 (1990); S. E. Wenzel, J. V. Westcottt, G. L. Larsen, J. Allergy Clin. Immunol. 87, 540 (1991); S. O'Sullivan, Acta Physiol. Scand. Suppl. 644, 1 (1999).
11. J. J. Murray et al., N. Engl. J. Med. 315, 800 (1986); M. C. Liu et al., Am. Rev. Respir. Dis. 142, 126 (1990); S. E. Wenzel, J. V. Westcottt, G. L. Larsen, J. Allergy Clin. Immunol. 87, 540 (1991); S. O'Sullivan, Acta Physiol. Scand. Suppl. 644, 1 (1999).
12. J. J. Murray et al., N. Engl. J. Med. 315, 800 (1986); M. C. Liu et al., Am. Rev. Respir. Dis. 142, 126 (1990); S. E. Wenzel, J. V. Westcottt, G. L. Larsen, J. Allergy Clin. Immunol. 87, 540 (1991); S. O'Sullivan, Acta Physiol. Scand. Suppl. 644, 1 (1999).
13. J. J. Murray et al., N. Engl. J. Med. 315, 800 (1986); M. C. Liu et al., Am. Rev. Respir. Dis. 142, 126 (1990); S. E. Wenzel, J. V. Westcottt, G. L. Larsen, J. Allergy Clin. Immunol. 87, 540 (1991); S. O'Sullivan, Acta Physiol. Scand. Suppl. 644, 1 (1999).
14. M. Hirata, A. Kakizuka, M. Aizawa, F. Ushikubi, S. Narumiya, Proc. Natl. Acad. Sci. U.S.A. 91, 11192 (1994).
15. Murine DP genomic clones were isolated from a 129/Sv genomic DNA library (Stratagene) with the corresponding cDNA as a probe. The targeting vector was constructed by inserting the neomycin resistance gene (pMC1-neo, Stratagene) into a unique Nhe I site of the first coding exon; this insertion disrupts the DP gene in the sequence encoding the third transmembrane domain of the protein. The herpes simplex virus thymidine kinase gene was inserted upstream. The targeting vector was linearized and introduced into E14-1 embryonic stem cells from 129/Ola mice by electroporation. Clones resistant to both G418 and gancyclovir were isolated and screened for homologous recombination by PCR amplification. Recombination was then confirmed by Southern blot hybridization. Two lines of embryonic stem cells were injected into C57BL/6 blastocysts to generate chimeric male offspring, which were then mated with C57BL/6 females. Pups with an agouti coat were genotyped by Southern blot analysis for determination of germ line transmission. Polyadenylated RNA was prepared from various organs, which were rapidly removed and homogenized in 10 volumes of Trizol (Gibco-BRL) with a Polytron homogenizer. RT-PCR analysis was performed with 10 μg of polyadenylated RNA with the forward primer, 5′-TCGGTCTTTTATGTGCTCG-TG-3′, corresponding to amino acids 57 to 63 in the first coding exon, and the reverse primer, 5′-TCCACGTTACTTTGCTGGGAA-3′, corresponding to amino acids 346 to 353 in the second coding exon. Northern blot analysis was performed on 10 μg of polyadenylated RNA as described [H. Oida et al., FEBS Lett. 417, 53 (1997)].
16. 2 or BW245C was measured.
17. H. Giles, P. Leff, M. L. Bolofo, M. G. Kelly, A. D. Robertson, Br. J. Pharmacol. 96, 291 (1989).
18. 5 littermates.
19. A. F. Walls et al., Lung 169, 227 (1991); N. C. Turner and C. T. Dollery, Br. J. Pharmacol. 93, 751 (1988).
20. A. F. Walls et al., Lung 169, 227 (1991); N. C. Turner and C. T. Dollery, Br. J. Pharmacol. 93, 751 (1988).
21. H. Tanaka, H. Nagai, Y. Maeda, Life Sci. 62, 169 (1998).
22. 2+-free phosphate-buffered saline (PBS) containing 0.1% (w/v) bovine serum albumin and 0.05 mM EDTA. The BAL fluid obtained from each animal was pooled and centrifuged at 150g for 10 min at 4°C. Cell pellets were resuspended in the same solution, and the number of nucleated cells staining with Türk solution was counted. Smears of cell suspensions were prepared with the use of a Cytospin II cytocentrifuge, stained with May-Grüwald-Giemsa dye, and subjected to a differential count of at least 300 cells under a microscope.
23. Mice were anesthetized with sodium pentobarbital (80 mg/kg, ip), and the tail vein was cannulated. The animals were injected intravenously with pancuronium bromide (0.1 mg/kg) and ventilated with the aid of a rodent ventilator at a rate of 60 strokes per minute and a stroke volume of 0.6 ml of air supplemented with oxygen. Airway resistance was measured according to the overflow method described by H. Konzett and R. Rössler [Arch. Exp. Pathol. Pharmakol. 195, 71 (1940)] with the use of a Ugo Basil 7020 bronchospasm transducer connected to the tracheal cannula. Increasing doses of acetylcholine (31.25 to 2000 (μg/kg) were injected into the tail vein, and the changes in overflow volume were determined. The increase in respiratory overflow volume induced by acetylcholine was expressed as a percentage of the maximal overflow volume obtained by clamping the trachea! cannula.
24. -1- mice 8 hours after the last inhalation of OVA, and the concentrations of IL-4, IL-5, IL-13, and IFN-γ in the fluid were determined by enzyme-linked immunosorbent assay.
25. Twenty-four hours after the last OVA inhalation, mice were anesthetized with sodium pentobarbital, and 10% (v/v) formalin in PBS was infused into the lung for fixation. The lung was then sectioned and stained either with hematoxylin and eosin or with periodic acid-Schiff reagent.
26. T. Aikawa et al., Chest 101, 916 (1992); J. A. Rankin et al., Proc. Natl. Acad. Sci. U.S.A. 93, 7821 (1996).
27. T. Aikawa et al., Chest 101, 916 (1992); J. A. Rankin et al., Proc. Natl. Acad. Sci. U.S.A. 93, 7821 (1996).
28. A. Mizoguchi et al., Proc. Natl. Acad. Sci. U.S.A, in press.
29. T. Matsuoka et al., unpublished data.
30. D. L Emery, T. D. Djokic, P. D. Graf, J. A. Nadel, J. Appl. Physiol. 67, 959 (1989).
31. Y. Fujitani and Y. Urade, unpublished data.
32. -1- mice. However, for excessive OVA challenges that induced infiltration of ∼70 × 10s cells in wild-type mice, a similar number of cells was detected in the BAL fluid of DP-1- mice.
33. Y. Urade, M. Ujihara, Y. Horiguchi, K. Ikai, O. Hayaishi, J. Immunol. 143, 2982 (1989).
34. K. Ikai, K. Danno, T. Horio, S. Narumiya, J. Invest. Dermatol. 85, 82 (1985); R. M. Barr et al., Br. J. Pharmacol. 94, 773 (1988); P. H. Howarth, Allergy 52, 12 (1997).
35. K. Ikai, K. Danno, T. Horio, S. Narumiya, J. Invest. Dermatol. 85, 82 (1985); R. M. Barr et al., Br. J. Pharmacol. 94, 773 (1988); P. H. Howarth, Allergy 52, 12 (1997).
36. K. Ikai, K. Danno, T. Horio, S. Narumiya, J. Invest. Dermatol. 85, 82 (1985); R. M. Barr et al., Br. J. Pharmacol. 94, 773 (1988); P. H. Howarth, Allergy 52, 12 (1997).
37. T. Tsuri et al., J. Med. Chem. 40, 3504 (1997).
38. Statistical significance was evaluated by one-way analysis of variance followed by Student's t test for unpaired values.
39. We thank K. Ishikawa, Y. Kataoka, K. Deguchi, and T. Obata for technical assistance; T. Arai and H. Nose for secretarial assistance; T. Tanaka and M. Kitaichi for discussions; and O. Hayaishi for encouragement. Supported in part by grants from the Uehara Memori, Foundation and the Smoking Research Foundation.